ZNTL Projected Dividend Yield
Zentalis Pharmaceuticals Inc ( NASDAQ : ZNTL )Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Co. is developing a pipeline of product candidates with an initial focus on validated oncology targets. Co. has two primary product candidates: ZN-c3, an inhibitor of Wee1, a protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. Co.'s other clinical product candidates include ZN-d5, a selective inhibitor of B-cell lymphoma 2 and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor. 20 YEAR PERFORMANCE RESULTS |
ZNTL Dividend History Detail ZNTL Dividend News ZNTL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |